Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN) : real-world experience in three European countries

  • Aims: The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study collecting real-world data on the safety and effectiveness of the 0.2 µg/day fluocinolone acetonide (FAc) implant in patients treated according to the European label requirements. Methods: Patients included in this analysis were treated for the licensed indication of chronic diabetic macular oedema (cDMO; that is, DMO that persists or recurs despite treatment). Data presented in the current analysis were collected from patient records up to 6 March 2017. Visual acuity (VA) data, including mean change in VA over time and at last observation, intraocular pressure (IOP) over the course of the study, IOP events, use of IOP-lowering therapy and cup:disc ratio were analysed. Information on additional DMO treatments post-FAc implant was also captured. Results: Five hundred and sixty-three patients (593 eyes) were enrolled on the study. Mean IOP for the overall population remained within the normal range throughout follow-up and 76.7% of patients did not require IOP-lowering therapy following treatment with the FAc implant. Sixty-nine per cent of eyes did not require additional DMO treatments. Mean VA in the overall population increased from 51.9 letters at baseline to 55.6 letters at month 12, with a significant increase of 2.9 letters at last observation. Patients with short-term cDMO experienced greater VA gains than those with long-term cDMO. Conclusions: The results of this analysis are comparable with those of other studies, including the Fluocinolone Acetate for Macular Edema study. The study reinforces the good safety and effectiveness profile of FAc, and demonstrates the benefit of early FAc treatment.
Metadaten
Author:Usha Chakravarthy, Simon R. Taylor, Frank H. Koch, João Paulo Castro de Sousa, Clare Bailey
URN:urn:nbn:de:hebis:30:3-477091
DOI:https://doi.org/10.1136/bjophthalmol-2018-312284
ISSN:1468-2079
ISSN:0007-1161
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/30242062
Parent Title (English):British journal of ophthalmology
Publisher:BMJ Publ. Group
Place of publication:London
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/09/21
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Contributing Corporation:ILUVIEN Registry Safety Study (IRISS) Investigators Group
Release Date:2018/10/23
Tag:clinical trial; macula; pharmacology; retina
Volume:102
Page Number:6
First Page:1
Last Page:6
Note:
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
HeBIS-PPN:439187214
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (English):License LogoCreative Commons - Namensnennung-Nicht kommerziell 4.0